News& Outreach*

News from mainstream media*

Our RISEbrain partners have been published and featured in top media outlets and conferences.

11/07/2024

Interview

Manuel Valiente, ‘Making your research translatable’

The European Association for Cancer Research (EACR)

24/01/2024

News

Living Biobank Of Brain Metastasis Samples Enabling ‘Personalized Medicine 2.0’

Clinical Research News

30/08/2023

NEWS

Un estudio descubre que los tumores cerebrales ‘hackean’ la comunicación entre neuronas

Telemadrid. Video.

26/06/2023

News

Neurociencia del cáncer: así secuestran los tumores el sistema nervioso para crecer más rápido

El País

Public outreach activities

Closing women’s health inequality gaps

News

Nanotechnology: a portable device against cervical cancer

Grants

EMBO Installation Grant, TUBITAK National Outstanding Researchers Program

Awards

AXA research fund fellowship, ETH postdoctoral fellowship

2018

Scientific activities

A portable device against cervical cancer

2023

Clinical studies (Immune monitoring performed by Schmitz group)

A phase II single arm clinical trial of a tailored immunotherapy approach with nivolumab in subjects with metastatic or advanced transitional cell carcinoma

2023

Clinical studies (Immune monitoring performed by Schmitz group)

A phase II single arm clinical trial of a tailored immunotherapy approach with nivolumab in subjects with metastatic or advanced renal cell carcinoma

2023

Characterization of the immune architecture and immunomodulatory capabilities of melanoma-derived brain metastases

Funding Organisation: Federal Ministry of Education and Research

2023

Grants

SaxoCell: Development of theranostic target molecules for diagnosis and therapy

Funding Organisation: Federal Ministry of Education and Research

2023

Grant for internationalization

Molecular dissection of ovarian cancer brain metastasis microenvironment through spatial transcriptomics

Project partners: Pathology unit, Department of Medical Sciences, University of Turin, Italy and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College, London, UK

Amount: 55.481,46€

2023

Clinical studies

SILMET

A controlled, randomized, double-blind clinical trial to evaluate the efficacy of SILbinin versus placebo to prevent recurrence after surgical resection of a single brain METastasis from non-small cell lung carcinoma or breast carcinoma

10/2013

Invited Speaker

European Macrophage and Dendritic cell society (EMDS) meeting

VIB Ghent, Belgium

06/2023

Invited speaker

European Hematology Association Annual meeting

Frankfurt, Germany

02/2023

Delegation member

EMBO India Research Partnership Tour

India